Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025

LONDON, June 24, 2015 /PRNewswire/ --

Treating diabetes - benefit your influence by finding new R&D trends and sales prospects

Discover the future of antidiabetic medicines. For those treatments, now get new revenue predictions, also exploring research and development. Discover diabetes market size and business potentials. And assess results, trends, technologies, therapies and opportunities.

Visiongain's updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You stay ahead in data on treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.

See what's possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines' predicted revenue.

Forecasts to 2025 and other analyses explain and predict the diabetes treatment market
Why miss data you need? Why struggle to find it? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.

That study also shows 90 tables, 91 charts and two interviews. Our work's purpose is to predict that industry's future, helping your research, analyses and decisions. See there how you can benefit your reputation for commercial insight, also helping your influence.

Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities lie.

Though no such study covers everything on treating high blood sugar, the following sections show how our new investigation benefits your work.

Forecasting of that world market and its segments - what does the future hold?
What are the secrets of that industry's progress? Where's it heading? Discover in our report overall world revenue prediction to 2025 for antidiabetic pharmaceuticals, with discussions.

Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level:
• Human insulins and analogues
• Dipeptidyl peptidase-4 inhibitors (DPP-4)
• Biguanides
• Glucagon-like peptide-1 receptor agonists (GLP-1)
• Sulfonylureas.

To see a report overview please email Sara Peerun on [email protected]

And these treatment categories:
• Thiazolidinediones
• Alpha-glucosidase inhibitors
• Meglitinides
• Sodium-glucose co-transporter-2 inhibitors (SGLT2)
• Other agents (grouped).

There assess outlooks for revenue expansion, hearing where you can profit. Find the diabetes market size from 2015. You investigate competition and rising sales. And you examine technological, clinical and commercial possibilities.

Also find top medicines' revenue potentials.

Predictions of leading products' sales - see what's possible, where you can gain
How will individual drugs for elevated blood sugar perform to 2025 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents:
• Lantus
• Januvia
• NovoLog and NovoMix
• Levemir
• Humalog
• Victoza
• Janumet
• Humulin.

There you find drugs and years with highest predicted sales. You also examine competitors. So discover what's happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.

That work also gives geographical sales predictions.

National markets - what outlooks for treatment demand and revenues?
In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2015 to 2025. See where, how and what's possible.

Our analyses show you individual revenue forecasts to 2025 for 11 national markets:
• United States (US)
• Japan
• EU leaders - Germany, France, the UK, Italy and Spain (EU5)
• BRIC nations - Brazil, Russia, India and China.

There you explore progress, needs and opportunities. What events change that market and outlooks for payers and patients? Our work shows you, discussing trends and demands.

To see a report overview please email Sara Peerun on [email protected]

Events affecting developers, producers and sellers of those metabolic treatments
That report also explains issues, forces and events affecting the antidiabetics industry and market from 2015, including these influences:
• Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates
• Governmental investment and collaboration between pharmaceutical companies
• Combination therapies for type 2 diabetes
• Competition from biosimilars and generic drugs - approvals and product launches.

And these issues, among others:
• Disease incidence and prevalence
• Risk factors - obesity and pre-diabetes, related metabolic conditions
• Drug delivery - technologies for introducing insulin and oral drugs
• New classes of antidiabetic medications and regulatory challenges
• Type 1 diabetes vaccine - new treatment approaches, including disease prevention.

Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you investigate what stimulates and restrains that biopharma, affecting its results. Also see prospects for small-molecule therapies.

Analysis of firms and potential for rising sales - what overall revenues possible?
What happens next? Our study predicts that world market will rise to $72.6bn in 2019, with high, expanding revenues from 2015 to 2025. See what's possible.

Our analysis covers organisations shaping that industry:
• Novo Nordisk
• Eli Lilly
• Novartis
• AstraZeneca
• Merck & Co.

Also investigate these leading companies, among other firms, including specialists in metabolic disorders:
• Boehringer Ingelheim
• Takeda
• Sanofi
• Bayer
• Pfizer.

And gain interviews with two other authorities on diabetes treatments. Our survey explores issues affecting that healthcare industry's present and future.

From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.

WaysDiabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025  helps
In particular, our new investigation gives this knowledge to benefit your work:
• Antidiabetic drug revenues to 2025 at overall world level, for 9 therapeutic submarkets and 31 products - assess outlooks for production, marketing and sales
• Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia - investigate developed and developing countries for demand and revenue potentials
• Prospects for established competitors, rising companies and new entrants - explore portfolios, opinions, results, strategies, technologies and outlooks for success
• Review of R&D pipelines - examine progress in research and development, finding technological and medical prospects
• Analysis of what stimulates and restrains that industry and market - gauge challenges and strengths, helping you compete, gain advantages and succeed.

That study, done in-house by our UK-based analysts, helps your knowledge and authority.

Information found nowhere else, helping your searches, analyses and plans - your success
And how can you be sure we know our subject? That's a fair point. We do so by getting the most from data, interpreting its meaning for business now and the future.

We digest publications and survey authorities, saving you time and difficulty, helping your planning and decisions. You hear what's happening, getting a feel for companies' prospects.

And our study gives independent analysis. There you get competitive intelligence found only in our report, finding where progress, money and opportunities lie. See what's possible.

Does that work answer every question? No, though it assesses diabetes medicines, their producers and commercial outlooks in detail. That way you find potential gains, discovering opportunities to harness, as well as benefiting your influence.

Trying our investigation now lets you see opportunities and revenue predictions
So with our survey you're less likely to fall behind in knowledge or miss opportunity. There find how to save time and effort, also benefiting your insight, authority and competing.

Our new analysis helps professionals like you assess the market for diabetes treatments. There you explore trends, discussions and sales forecasting. Avoid missing out in knowledge. Benefit by getting that report here now.

To see a report overview please email Sara Peerun on [email protected]

Companies and Other Organisations in the Study 

Actavis
Alphapharm
American Diabetes Association
Amylin Pharmaceuticals (acquired by Bristol Myers Squibb)
Andromeda Biotech
Arisaph
Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil)
Astellas Pharma
AstraZeneca
Bayer
Biocon
Blue Cross
Bristol-Myers Squibb
Biogen Idec
Boehringer Ingelheim
Boston Therapeutics
Chugai Pharmaceutical
Diabetes UK
DiaMedica
Diamyd Medical
Eisai
Eli Lilly
European Medicines Agency (EMA)
Express Scripts
Food and Drug Administration (US FDA)
Franco-Indian Pharmaceuticals
Furiex Pharmaceuticals
Genentech
Generex Biotechnology Corporation
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
Google
Human Genome Sciences
Intarcia
International Diabetes Federation (IDF)
Janssen (subsidiary of J&J)
Johnson & Johnson (J&J)
Lupin
Kissei Pharmaceuticals
Kotobuki Pharma
Kowa
MannKind Corporation
Mascot Health Series
Merck & Co.
Merck Serono
Ministry of Health (MoH, Germany)
Ministry of Health, Labour and Welfare (MHLW, Japan)
MSD KK (Asian subsidiary of Merck & Co.)
Mylan
National Health Service (NHS, UK)
National Institute of Health and Clinical Excellence (NICE, UK)
Novartis
Novo Nordisk
Ono Pharmaceuticals
Oramed Pharmaceuticals
Patheon
Pfizer
Ranbaxy Laboratories
Roche
Salix Pharmaceuticals
Sandoz
Sanofi
Santarus (bought by Salix Pharmaceuticals)
Servier
Shantha Biotechnics (acquired by Sanofi)
Shionogi Pharmaceuticals
Shreya Life Sciences
Stanford University School of Medicine
Sun Pharma
Takeda
Taisho Pharmaceutical
Teva Pharmaceutical Industries
Transdermal Specialities
United States Diabetes Prevention Program (DPP)
World Health Organization (WHO)
Yabao Pharmaceutical
Zydus Cadila

To request an exec summary of this report please email Sara Peerun at [email protected] or call Tel: +44-(0)-20-7336-6100

Or click on https://goo.gl/ra5s3R

SOURCE Visiongain